Kiran Mazumdar-Shaw, Chairperson of major drugmaker Biocon Ltd., urged the government to eliminate tax on drugs for cancer treatment and for chronic and rare diseases, ahead of the budget 2025 ...

Divis Labs has been an outperformer in the pharma pack so far in this series, as most of the pharma stocks have corrected in the January series, apart from a few like Divis Labs and Biocon.

Hence, we recommend buying Reliance Industries around Rs 1,290. Biocon is reflecting strong volumes over the past week, indicating growing investor interest. The stock is approaching a critical ...

Founded in 2022, Bengaluru-based Fermbox Bio uses precision fermentation and synthetic biology to programme microorganisms and produce bio-based enzymes and technologies to manufacture biofuels ...

Indian firms such as Sun Pharma, Dr. Reddy’s, Laboratories and Biocon are set to gain from this. Beyond generics, biosimilars present another growth avenue. "The upcoming patent expirations will ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Mylan and Biocon got their Herceptin biosimilar approved by the FDA in December 2017, followed by Samsung Bioepis early this year. There was no word from Amgen and Allergan about when they plan to ...

Mylan and Biocon Biologics’ Semglee was the first insulin product deemed a biologic under section 351(a) per the Biologics Price Competition and Innovation Act (BPCIA) and is now under review ...

Josh Gissing is Cluster Head (UK, Ireland & Nordics) for Biocon Biologics: a biosimilars company whose business model seeks to make biologic therapies affordable, accessible and available to all. He ...